Abstract
Adherence to hepatitis C virus (HCV) therapy has been incompletely examined among HIV-infected patients. We assessed changes
in interferon and ribavirin adherence and evaluated the relationship between adherence and early (EVR) and sustained virologic
response (SVR). We performed a cohort study among 333 HIV/HCV-coinfected patients who received pegylated interferon and ribavirin
between 2001 and 2006 and had HCV RNA before and after treatment. Adherence was calculated over 12-week intervals using pharmacy
refills. Mean interferon and ribavirin adherence declined 2.5 and 4.1 percentage points per 12-week interval, respectively.
Among genotype 1/4 patients, EVR increased with higher ribavirin adherence, but this association was less strong for interferon.
SVR among these patients was higher with increasing interferon and ribavirin adherence over the first, second, and third,
but not fourth, 12-week intervals. Among HIV/HCV patients, EVR and SVR increased with higher interferon and ribavirin adherence.
Adherence to both antivirals declined over time, but more so for ribavirin.
in interferon and ribavirin adherence and evaluated the relationship between adherence and early (EVR) and sustained virologic
response (SVR). We performed a cohort study among 333 HIV/HCV-coinfected patients who received pegylated interferon and ribavirin
between 2001 and 2006 and had HCV RNA before and after treatment. Adherence was calculated over 12-week intervals using pharmacy
refills. Mean interferon and ribavirin adherence declined 2.5 and 4.1 percentage points per 12-week interval, respectively.
Among genotype 1/4 patients, EVR increased with higher ribavirin adherence, but this association was less strong for interferon.
SVR among these patients was higher with increasing interferon and ribavirin adherence over the first, second, and third,
but not fourth, 12-week intervals. Among HIV/HCV patients, EVR and SVR increased with higher interferon and ribavirin adherence.
Adherence to both antivirals declined over time, but more so for ribavirin.
- Content Type Journal Article
- Category Original Paper
- Pages 1-10
- DOI 10.1007/s10461-012-0288-9
- Authors
- Vincent Lo Re III, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Valerie Teal, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA
- A. Russell Localio, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA
- Valerianna K. Amorosa, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- David E. Kaplan, Medicine Service, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
- Robert Gross, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Journal AIDS and Behavior
- Online ISSN 1573-3254
- Print ISSN 1090-7165